(R)-1-[2-(methyloxy)-4-nitrophenyl]-3-pyrrolidinol | 851690-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-1-[2-(methyloxy)-4-nitrophenyl]-3-pyrrolidinol
• 英文别名: (R)-1-(2-methoxy-4-nitro-phenyl)-pyrrolidin-3-ol；(3R)-1-(4-nitro-2-methoxyphenyl)pyrrolidin-3-ol；(R)-1-(2-methoxy-4-nitrophenyl)pyrrolidin-3-ol；(3R)-1-(2-methoxy-4-nitrophenyl)pyrrolidin-3-ol
• CAS: 851690-75-0
• 化学式: C₁₁H₁₄N₂O₄
• 分子量: 238.243
• InChiKey: MMNOBTOOAAADKJ-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  78.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-1-[2-(methyloxy)-4-nitrophenyl]-3-pyrrolidinol 在 palladium hydroxide on carbon 氢气 、 苯酚 作用下， 以 1,4-二氧六环 为溶剂， 130.0 ℃ 、310.27 kPa 条件下， 反应 3.0h， 生成 6-(4-chlorophenyl)-3-{4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-methoxyphenyl}thieno[3, 2-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  [EN] 3-(4-AMINOPHENYL) THIENOPYRIMID-4-ONE DERIVATIVES AS MCH R1 ANTAGONISTS FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY
  [FR] DERIVES DE 3-(4-AMINOPHENYL)-THIENOPYRIMID-4-ONE UTILISES COMME ANTAGONISTES DE MCH R1 POUR LE TRAITEMENT DE L'OBESITE, DU DIABETE, DE LA DEPRESSION ET DE L'ANXIETE

  摘要：

  这项发明涉及一种新型芳基胺，它们是黑素浓集激素受体1（MCH R1）的拮抗剂，以及含有它们的药物组合物，它们的制备方法，以及它们在治疗肥胖、糖尿病、抑郁症和/或焦虑症的药物中的应用。该发明的化合物具有以下结构式：

  公开号：

  WO2005042541A1
• 作为产物：
  描述：

  2-氯-5-硝基茴香醚 、 (R)-3-吡咯烷醇 在 Brine 作用下， 以 二氯甲烷 、 sodium hydroxide 为溶剂， 反应 16.0h， 以to give (3R)-1-[2-(methyloxy)4-nitrophenyl]-3-pyrrolidinol (10.8 g, 0.045 mol, 91%)的产率得到(R)-1-[2-(methyloxy)-4-nitrophenyl]-3-pyrrolidinol
  参考文献：
  名称：

  Arylamine mch r1 antagonists

  摘要：

  本发明涉及一种新型芳基胺，其为黑色素浓聚激素受体1（MCH R1）的拮抗剂，涉及含有它们的制药组合物、它们的制备过程以及它们在治疗肥胖症、糖尿病、抑郁症和/或焦虑症的药物中的用途。本发明的化合物具有以下公式：

  公开号：

  US20070078125A1

文献信息

• [EN] AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR-1 D'HORMONE DE MÉLANO-CONCENTRATION D'AZOLOTRIAZINONE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010042682A1

  公开（公告）日：2010-04-15

  The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I, wherein R1, is selected from the group consisting of monocyclic aryl or monocyclic heteroaryl; W is selected from the group consisting of a direct bond, -O-, and -N(R6)-; provided that if W is a direct bond, D is a cyclic amine that is attached to A via the nitrogen atom of the cyclic amine; D is selected from the group consisting of a direct bond, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, cycloalkylalkyl, and 4- to 6-membered cyclic amines, provided that if D is a direct bond, R2a, R2b, and R2c must be selected from H, alkyl, or cycloalkyl; E and G are independently N or CH provided that both are not N; R1 is substituted or unsubstituted phenyl or substituted or unsubstituted monocyclic heteroaryl; R2a, R2b, and R2c are independently selected from the group consisting of hydrogen, halo, cyano, hydroxyl, -NR5R5a, -SO2R34, -CO2R35 -NR5CO2R21, -NR5COR21, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, substituted or unsubstituted 4- to 6-membered cyclic amines wherein said cyclic amine is optionally substituted with -OH, carbonylamino, alkoxycarbonylamino, or at least one of R2a, R2b, and R2c is a prodrug moiety selected from amino acid esters or phosphoric acid esters wherein said amino acid ester has the formula -OC(O)CH(NH2)R31, wherein R31 is H or C1 to C4 alkyl; or any two of R2a, Rb, or R2c, may be taken together to form a ring; R3 and R3a are each independently selected from the group consisting of hydrogen, hydroxyl, lower alkoxy, halo, CN, substituted or unsubstituted C1 to C4 alkyl, perfluoroalkyl, substituted or unsubstituted C3 to C7 cycloalkyl, cycloalkoxy, amino, alkylamino, dialkylamino, and aminoalkyl, wherein R3 or R3a and D may optionally be taken together with the atoms to which they are attached to form a 5- to 7-membered ring; R5 and R5a are the same or different and are independently selected from the group consisting of hydrogen, substituted or unsubstituted lower alkyl, hydroxyalkyl, hydroxyalkylcycloalkyl, substituted or unsubstituted heterocycloalkyl, acyl, alkoxycarbonyl, carboxyalkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted cycloalkylalkyl, wherein the R5 and R5a groups and the N atom to which they are attached may form a ring; R21 and R31 are each H or C1 to C4 alkyl; R34 is alkyl; R35 is H or alkyl; and R6 is selected from the group consisting of H, C1 to C4 alkyl and C3 to C7 cycloalkyl.

  本申请提供了作为MCHR1拮抗剂有用的化合物，特别用于肥胖症的治疗，包括所有立体异构体、溶剂化合物、前药和根据式I的药学上可接受的形式，其中R1从单环芳基或单环杂芳基组成的群体中选择；W从直接键、-O-和-N(R6)-组成的群体中选择；条件是如果W是直接键，则D是通过环胺的氮原子连接到A的环胺；D从直接键、取代或未取代的C1到C4烷基、取代或未取代的C3到C7环烷基、环烷基烷基和4-到6-成员环胺组成的群体中选择，条件是如果D是直接键，则R2a、R2b和R2c必须从H、烷基或环烷基中选择；E和G独立地是N或CH，条件是两者都不是N；R1是取代或未取代的苯基或取代或未取代的单环杂芳基；R2a、R2b和R2c独立地从氢、卤素、氰基、羟基、-NR5R5a、-SO2R34、-CO2R35 -NR5CO2R21、-NR5COR21、取代或未取代的C1到C4烷基、取代或未取代的C3到C7环烷基、取代或未取代的4-到6-成员环胺中选择，其中所述环胺可以选择地取代为-OH、羰基氨基、烷氧羰基氨基，或R2a、R2b和R2c中的至少一个是选择自氨基酸酯或磷酸酯的前药基团，其中所述氨基酸酯具有式-OC(O)CH(NH2)R31，其中R31为H或C1到C4烷基；或R2a、Rb或R2c中的任意两个可以结合形成环；R3和R3a各自独立地从氢、羟基、较低烷氧基、卤素、CN、取代或未取代的C1到C4烷基、全氟烷基、取代或未取代的C3到C7环烷基、环烷氧基、氨基、烷基氨基、二烷基氨基和氨基烷基中选择，其中R3或R3a和D可以选择地结合形成5-到7-成员环；R5和R5a相同或不同，独立地从氢、取代或未取代的较低烷基、羟基烷基、羟基烷基环烷基、取代或未取代的杂环烷基、酰基、烷氧羰基、羧基烷基、取代或未取代的环烷基和取代或未取代的环烷基烷基中选择，其中R5和R5a基团和它们连接的N原子可以形成环；R21和R31各自为H或C1到C4烷基；R34为烷基；R35为H或烷基；R6从H、C1到C4烷基和C3到C7环烷基中选择。
• Arylamine mch r1 antagonists
  申请人：Barvian K. Kevin

  公开号：US20070078125A1

  公开（公告）日：2007-04-05

  This invention relates to novel arylamines which are antagonists of the melanin-concentrating hormone receptor 1 (MCH R1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines for the treatment of obesity, diabetes, depression, and/or anxiety. Compounds of the invention have the formula:

  本发明涉及一种新型芳基胺，其为黑色素浓聚激素受体1（MCH R1）的拮抗剂，涉及含有它们的制药组合物、它们的制备过程以及它们在治疗肥胖症、糖尿病、抑郁症和/或焦虑症的药物中的用途。本发明的化合物具有以下公式：
• THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS
  申请人：Amegadzie Albert Kudzovi

  公开号：US20090233919A1

  公开（公告）日：2009-09-17

  The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R 1 , q, p, R 2 , t, Ar 1 , L 1 , R 3 and R 4 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

  本发明涉及一种公式（I）的黑色素浓集激素拮抗剂化合物；其中w，R1，q，p，R2，t，Ar1，L1，R3和R4如定义所述，或其药学上可接受的盐，溶剂和对映体，用于治疗，预防或缓解与肥胖和相关疾病相关的症状。
• Therapeutic Agents
  申请人：Giordanetto Fabrizio

  公开号：US20080221107A1

  公开（公告）日：2008-09-11

  Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

  公式(I)的化合物，制备这些化合物的方法，它们在肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫和相关疾病以及神经疾病，如痴呆、多发性硬化症、帕金森病、亨廷顿舞蹈症和阿尔茨海默病以及与疼痛有关的疾病的治疗中的用途，以及含有它们的制药组合物。
• NOVEL MCH RECEPTOR ANTAGONISTS
  申请人：Arnold Macklin Brian

  公开号：US20090093456A1

  公开（公告）日：2009-04-09

  The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R 1 , R a , R b , R 2 , L 1 , R 3 , R 4 and R 5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.

  本发明涉及一种公式（1）的黑色素浓集激素拮抗剂化合物：其中R1、Ra、Rb、R2、L1、R3、R4和R5如定义所述，或其药学上可接受的盐、对映体、非对映体或其混合物，可用于治疗肥胖和相关疾病。